PROPHYLACTIC LAMIVUDINE TO IMPROVE THE OUTCOME OF BREAST CANCER PATIENTS WITH HBSAG POSITIVE DURING CHEMOTHERAPY: A META-ANALYSIS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ZHENG YIHU; ZHANG SHENGCHU; TAN GRAHN HOOI MIN; YE CHAO; GONG ZHENG; ZHANG QIYU

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Hepatitis Monthly Year:2013 | Volume:13 | Issue:4 Page(s): 1-10

Download Full-Text

View:

297

Download:

175

Cites:

Information Journal Paper

Title

PROPHYLACTIC LAMIVUDINE TO IMPROVE THE OUTCOME OF BREAST CANCER PATIENTS WITH HBSAG POSITIVE DURING CHEMOTHERAPY: A META-ANALYSIS

Author(s)

Keywords

BREAST NEOPLASMS

DRUG THERAPY

HEPATITIS B VIRUS

LAMIVUDINE

META-ANALYSIS

DRUG TOXICITY

PREVENTIVE MEDICIN

Abstract

Context: Raising the chemotherapy-induced HBV reactivation is parallel to the increment of chemotherapy treatments in breast cancer patients. This META-ANALYSIS aims to evaluate the efficacy of prophylactic use of LAMIVUDINE in breast cancer patients with HBsAg positive during chemotherapy.Evidence Acquisition: MEDLINE, Pubmed, Ovid and Embase were used to search for clinical studies comparing with or without prophylactic use of LAMIVUDINE for HBV reactivation in breast cancer patients receiving chemotherapy. Outcomes of interest were the rate of HBV reactivation, incidence of hepatitis and incidence of hepatitis attributable to HBV reactivation, severity of hepatitis and severity of hepatitis attributable to HBV reactivation, the rate of chemotherapy disruption, and the rate of chemotherapy disruption attributable to HBV reactivation, overall mortality, and mortality attributable to HBV reactivation.Results: Four studies with 285 patients were included in this META-ANALYSIS. The rate of HBV reactivation, incidence of hepatitis and incidence of hepatitis related to HBV reactivation were reduced by use of prophylactic LAMIVUDINE compared to control group. Pooled Odds Ratios (ORs) were 0.09 (95% confidence intervals [CI] 0.03-0.26; P<0.0001), 0.23 (95% CI 0.06-0.92; P=0.04), and 0.10 (95% CI 0.03-0.32; P<0.0001) respectively. There was a reduction in chemotherapy disruption related to HBV reactivation by use of prophylactic LAMIVUDINE (pooled OR=0.11; 95% CI 0.02-0.58; P=0.01). Chemotherapy disruption, overall mortality, and mortality attributable to HBV reactivation were not significantly different between two groups. Pooled ORs were 0.42 (95% CI 0.11-1.58; P=0.20), 0.37 (95% CI 0.07-2.04; P=0.25), and 0.25 (95% CI 0.01-6.82; P=0.41) respectively. LAMIVUDINE was well-tolerated, and no additional toxicity was observed.Conclusions: Use of prophylactic LAMIVUDINE may have positive effect on the outcome of breast cancer patients with HBsAg positive during chemotherapy.

Cites

No record.

References

No record.

Cite

APA: Copy

ZHENG, YIHU, ZHANG, SHENGCHU, TAN GRAHN, HOOI MIN, YE, CHAO, GONG, ZHENG, & ZHANG, QIYU. (2013). PROPHYLACTIC LAMIVUDINE TO IMPROVE THE OUTCOME OF BREAST CANCER PATIENTS WITH HBSAG POSITIVE DURING CHEMOTHERAPY: A META-ANALYSIS. HEPATITIS MONTHLY, 13(4), 1-10. SID. https://sid.ir/paper/306743/en

Vancouver: Copy

ZHENG YIHU, ZHANG SHENGCHU, TAN GRAHN HOOI MIN, YE CHAO, GONG ZHENG, ZHANG QIYU. PROPHYLACTIC LAMIVUDINE TO IMPROVE THE OUTCOME OF BREAST CANCER PATIENTS WITH HBSAG POSITIVE DURING CHEMOTHERAPY: A META-ANALYSIS. HEPATITIS MONTHLY[Internet]. 2013;13(4):1-10. Available from: https://sid.ir/paper/306743/en

IEEE: Copy

YIHU ZHENG, SHENGCHU ZHANG, HOOI MIN TAN GRAHN, CHAO YE, ZHENG GONG, and QIYU ZHANG, “PROPHYLACTIC LAMIVUDINE TO IMPROVE THE OUTCOME OF BREAST CANCER PATIENTS WITH HBSAG POSITIVE DURING CHEMOTHERAPY: A META-ANALYSIS,” HEPATITIS MONTHLY, vol. 13, no. 4, pp. 1–10, 2013, [Online]. Available: https://sid.ir/paper/306743/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops